Stapled ACE2 alpha-helical peptides as SARS-CoV-2 spike protein blockers and virus entry inhibitors
- Funded by Auckland Medical Research Foundation (AMRF)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$58,028.53Funder
Auckland Medical Research Foundation (AMRF)Principal Investigator
Unspecified Unspecified UnspecifiedResearch Location
New ZealandLead Research Institution
University of AucklandResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The professor and doctor were awarded $96,457 to investigate whether existing patents for chemical manufacturing technology could be used to develop an effective anti-viral treatment for Covid-19. "We already hold patents for the chemical manufacturing technology we plan to use. This is an excellent opportunity to put New Zealand research in the global spotlight," said Professor Brimble. "While vaccine development is essential, this is predicted to take 18 months. Even if New Zealand successfully manages to avert the crisis through Government-enforced lockdown procedures, the country remains at significant threat from a second wave of outbreaks. "Effective anti-viral treatments are essential for the health and well-being of New Zealanders, particularly those of our most-at-risk demographics."